Effects of hydration in rats and mice with polycystic kidney disease

American Journal of Physiology - Renal Physiology

Volumn 308, Issue 3, 2015, Pages F261-F266

  Hopp, Katharina ^a   Wang, Xiaofang ^a   Ye, Hong ^a   Irazabal, María V ^a   Harris, Peter C ^a   Torres, Vicente E ^a  

^a MAYO CLINIC   (United States)

Author keywords

CAMP; Cyclic nucleotide phosphodiesterase; Hydration; Polycystic kidney disease; Vasopressin

Indexed keywords

AGAR; CYCLIC AMP; DESMOPRESSIN; GLUCOSE; PHOSPHODIESTERASE; POLYCYSTIN 1; VASOPRESSIN; ARGIPRESSIN; VASOPRESSIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; FEEDING; FEMALE; FLUID INTAKE; HOMOZYGOSITY; HYDRATION; KIDNEY MASS; KIDNEY PARENCHYMA; KIDNEY POLYCYSTIC DISEASE; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RAT; VASOPRESSIN RELEASE; ADVERSE EFFECTS; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRINKING; HYPODERMOCLYSIS; KIDNEY; METABOLISM; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; ARGININE VASOPRESSIN; DISEASE MODELS, ANIMAL; DRINKING; HYPODERMOCLYSIS; KIDNEY; MICE, INBRED C57BL; MICE, TRANSGENIC; POLYCYSTIC KIDNEY DISEASES; RATS; RECEPTORS, VASOPRESSIN;

EID: 84922216991     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00345.2014     Document Type: Article

References (34)

1. Ahrabi AK, Terryn S, Valenti G, Caron N, Serradeil-Le Gal C, Raufaste D, Nielsen S, Horie S, Verbavatz JM, Devuyst O. PKD1 haploinsufficiency causes a syndrome of inappropriate antidiuresis in mice. J Am Soc Nephrol 18: 1740-1753, 2007.
2. Aihara M, Fujiki H, Mizuguchi H, Hattori K, Ohmoto K, Ishikawa M, Nagano K, Yamamura Y. Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury. J Pharmacol Exp Ther 349: 258-267, 2014.
3. Bakeberg JL, Tammachote R, Woollard JR, Hogan MC, Tuan HF, van Deursen JM, Huang BQ, Torres VE, Harris PC, Ward CJ. Epitope-tagged Pkhd1 tracks the processing, secretion, and localization of fibrocystin. J Am Soc Nephrol 22: 2266-2277, 2011.
4. Bankir L. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovasc Res 51: 372-390, 2001.
5. Gallagher AR, Esquivel EL, Briere TS, Tian X, Mitobe M, Menezes LF, Markowitz GS, Jain D, Onuchic LF, Somlo S. Biliary and pancre- atic dysgenesis in mice harboring a mutation in Pkhd1. Am J Pathol 172: 417-429, 2008.
6. Garcia-Gonzalez MA, Menezes LF, Piontek KB, Kaimori J, Huso DL, Watnick T, Onuchic LF, Guay-Woodford LM, Germino GG. Genetic interaction studies link autosomal dominant and recessive polycystic kidney disease in a common pathway. Hum Mol Genet 16: 1940-1950, 2007.
7. Gattone VH 2nd, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9: 1323-1326, 2003.
8. Gattone VH, Maser RL, Tian C, Rosenberg JM, Branden MG. Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease. Dev Genet 24: 309-318, 1999.
9. Harris PC, Torres VE. Polycystic kidney disease, autosomal dominant. In: GeneReviews at GeneTests: Medical Genetics Information Resource (online). https://www.genetests.org/disorders/?disid 2140 [17 December 2014].
10. Hopp K, Hommerding CJ, Wang X, Ye H, Harris PC, Torres VE. Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model. J Am Soc Nephrol; ASN.2013121312.
11. Hopp K, Ward C, Hommerding C, Nasr S, Tuan H, Gainullin V, Rossetti S, Torres V, Harris P. Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity. J Clin Invest 122: 4257-4273, 2012.
12. Kusano E, Yoshida I, Takeda S, Homma S, Yusufi AN, Dousa TP, Asano Y. Nephron distribution of total low Km cyclic AMP phosphodiesterase in mouse, rat and rabbit kidney. Tohoku J Exp Med 193: 207-220, 2001.
13. Lager DJ, Qian Q, Bengal RJ, Ishibashi M, Torres VE. The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease. Kidney Int 59: 126-136, 2001.
14. Meijer E, Gansevoort RT, de Jong PE, van der Wal AM, Leonhard WN, de Krey SR, van den Born J, Mulder GM, van Goor H, Struck J, de Heer E, Peters DJ. Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug. Nephrol Dial Transplant 26: 2445-2453, 2011.
15. Moser M, Matthiesen S, Kirfel J, Schorle H, Bergmann C, Senderek J, Rudnik-Schoneborn S, Zerres K, Buettner R. A mouse model for cystic biliary dysgenesis in autosomal recessive polycystic kidney disease (ARPKD). Hepatology 41: 1113-1121, 2005.
16. Nagao S, Nishii K, Katsuyama M, Kurahashi H, Marunouchi T, Takahashi H, Wallace DP. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol 17: 2220-2227, 2006.
17. Robertson GL. The regulation of vasopressin funtion in health and disease. Recent Prog Horm Res 33: 333-385, 1997.
18. Schmitt F, Bresson JL, Beressi N, Bichet DG, Chauveau D, Bankir L. Influence of plasma amino acid level on vasopressin secretion. Diabetes Metab 29: 352-361, 2003.
19. Torres VE, Bankir L, Grantham JJ. A case for water in the treatment of polycystic kidney disease. Clin J Am Soc Nephrol 4: 1140-1150, 2009.
20. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367: 2407-2418, 2012.
21. Torres VE, Harris PC. Polycystic kidney disease: genes, proteins, animal models, disease mechanisms and therapeutic opportunities. J Intern Med 261: 17-31, 2007.
22. Torres VE, Harris PC. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J Am Soc Nephrol 25: 18-32, 2014.
23. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 369: 1287-1301, 2007.
24. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 10: 363-364, 2004.
25. Wang X, Gattone VH, Somlo S, Harris PC, VET. Effectiveness of OPC-41061 on polycystic kidney disease development in Pkd2WS25. J Am Soc Nephrol 2005, p. 361A.
26. Wang X, Gattone IIVH, Harris PC, Torres VE. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061. J Am Soc Nephrol 16: 846-851, 2005.
27. Wang X, Ward CJ, Harris PC, Torres VE. Cyclic nucleotide signaling in polycystic kidney disease. Kidney Int 77: 129-140, 2009.
28. Wang X, Wu Y, Ward CJ, Harris PC, Torres VE. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol 19: 102-108, 2008.
29. Wang X, Zhang S, Liu Y, Spichtig D, Kapoor S, Koepsell H, Mohebbi N, Segerer S, Serra AL, Rodriguez D, Devuyst O, Mei C, Wuthrich RP. Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats. Kidney Int 84: 962-968, 2013.
30. Ward CJ, Hogan MC, Rossetti S, Walker D, Sneddon T, Wang X, Kubly V, Cunningham JM, Bacallao R, Ishibashi M, Milliner DS, Torres VE, Harris PC. The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet 30: 259-269, 2002.
31. Williams SS, Cobo-Stark P, James LR, Somlo S, Igarashi P. Kidney cysts, pancreatic cysts, and biliary disease in a mouse model of autosomal recessive polycystic kidney disease. Pediatr Nephrol 23: 733-741, 2008.
32. Woollard JR, Punyashtiti R, Richardson S, Masyuk TV, Whelan S, Huang BQ, Lager DJ, vanDeursen J, Torres VE, Gattone VH, LaRusso NF, Harris PC, Ward CJ. A mouse model of autosomal recessive polycystic kidney disease with biliary duct and proximal tubule dilatation. Kidney Int 72: 328-336, 2007.
33. Wu G, D'Agati V, Cai Y, Markowitz G, Park JH, Reynolds DM, Maeda Y, Le TC, Hou J Jr, Kucherlapati R, Edelmann W, Somlo S. Somatic inactivation of Pkd2 results in polycystic kidney disease. Cell 93: 177-188, 1998.
34. Yang B, Bankir L. Urea and urine concentrating ability: new insights from studies in mice. Am J Physiol Renal Physiol 288: F881-F896, 2005.